Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071
Graphical abstract
Section snippets
Acknowledgments
The authors thank the NIH and NIMH for support of our M1 muscarinic program (1RO1MH082867-01). Vanderbilt is a Specialized Chemistry Center within the MLPCN (U54MH084659), and ML071 is an MLPCN probe, freely avaialble upon request.
References and notes (37)
Life Sci.
(1993)- et al.
Prog. Brain Res.
(2004) - et al.
Trends Pharmacol. Sci.
(2009) - et al.
Eur. J. Pharmacol.
(2009) - et al.
Neuron
(2006) - et al.
Curr. Opin. Chem. Biol.
(2008) - et al.
Neuropharmacology
(2010) - et al.
Bioorg. Med. Chem. Lett.
(2010) - et al.
Bioorg. Med. Chem. Lett.
(2010) - et al.
Bioorg. Med. Chem. Lett.
(2010)
Bioorg. Med. Chem. Lett.
(2011)
Bioorg. Med. Chem. Lett.
(2010)
Bioorg. Med. Chem. Lett.
(2011)
Br. J. Pharmacol.
(2006)
Nat. Rev. Drug Disc.
(2009)
Am. J. Psychol.
(2008)
Drug Rev.
(2003)
PNAS
(2003)
Cited by (0)
- †
Present address: NIH Chemical Genomics Center, National Institute of Health, Bethesda, MD, USA.
Copyright © 2011 Elsevier Ltd. All rights reserved.